View Older Stories View More Recent Stories
-
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
-
Form 4 Nuvalent, Inc. For: Jul 28 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, ARCH Venture Partners and Section 32, Announces Closing of $200 Million Initial Public Offering
-
Strata Oncology Completes $90 Million Series C Financing
-
Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers
-
Form 3 DA32 Life Science Tech For: Jul 27 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, Arch Venture Partners and Section 32, Announces Pricing of $200 Million Initial Public Offering
-
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
-
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
-
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
-
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
-
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
-
Axon Therapies Announces Chad Hoskins As Chief Executive Officer
-
Lumos Pharma (LUMO) issues new guidance concerning the Phase 2 OraGrowtH210 Trial of LUM-201 in PGHD
-
Lumos Pharma Announces Clinical Updates
-
Lumos Pharma Announces Clinical Updates
-
Humanity Health Launches to Address Lack of Diversity in Healthcare Leadership with Founding Investment from Deerfield Management
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Endologix LLC Receives FDA Breakthrough Device Designation for ChEVAS™ System
-
Publication relating to a transparency notification
-
Publication relating to a transparency notification
-
Moving Minds Launches New Fractional Chief Marketing Officer (CMO) Practice
-
Ribon Therapeutics Secures $65 Million Financing
-
Portable MRI Startup Hyperfine is Going Public After SPAC Merger With HealthCor Catalio
-
Hyperfine and Liminal Sciences to Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp. (HCAQ)
-
Hyperfine, Inc., Creator of the First FDA-Cleared Portable MRI Device, and Liminal Sciences, Inc. To Be Listed on Nasdaq Through a Business Combination With HealthCor Catalio Acquisition Corp.
-
Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
-
DFP Healthcare Acquisitions Corp. (DFPH) Announces Proposed Business Combination With The Oncology Institute
-
DFP Healthcare Acquisitions Corp. Announces Proposed Business Combination With The Oncology Institute
-
Novocardia™ Announces $53.7 Million Financing Led by Deerfield Management
-
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
-
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
-
Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases
-
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus
-
Demy-Colton Announces BioFuture™ Conference to be held at Cure, Deerfield’s Vertical Innovation Campus in New York City
-
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
-
Form SC 13D/A Deerfield Healthcare Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform
-
Deerfield Healthcare Technology Acquisitions Corp. (DFHT) Announces Closing of Business Combination With CareMax (CMAX)
-
Deerfield Healthcare Technology Acquisitions Corp. Announces Closing of Business Combination With CareMax
-
Deerfield Healthcare Technology Acquisitions Corp. Announces Stockholder Approval of Business Combination With CareMax
-
Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
-
Form 3 Singular Genomics System For: May 26 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Larimar Therapeutics (LRMR) Announces $95 Million Private Placement Financing of Common Stock, Warrants
-
Larimar Therapeutics Announces $95 Million Private Placement Financing
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
-
Form 4 Larimar Therapeutics, For: May 12 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
